{"schema_version":"secwatch.filing_event.v1","accession":"0001999480-25-000048","form_type":"8-K","ticker":"ANRO","cik":"0001999480","company_name":"Alto Neuroscience, Inc.","filed_at":"2025-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.661778+00:00","generated_at":"2026-05-20T02:03:00.948682+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Alto Neuroscience acquires two dopamine agonist candidates for TRD and Parkinson's","bullets":["Alto paid $1.75M cash plus $1.2M expense reimbursement upfront, with up to $71.5M in milestone payments ($41M commercial).","Acquired CTC-501 (renamed ALTO-207) for treatment-resistant depression and CTC-413 (ALTO-208) for Parkinson's disease.","Phase 2a of CTC-501 met primary endpoint; patients reached mean 4.1 mg/day, 67% achieved 5 mg, MADRS improvement d=1.1 (p=0.025).","Alto expects to initiate a potentially pivotal Phase 2b trial for ALTO-207 by mid-2026, with topline data in 2027.","Cash guidance unchanged; current cash expected to fund operations into 2028 through at least five planned clinical readouts."],"urls":{"canonical":"https://secwatch.observer/filing/0001999480-25-000048","json":"https://secwatch.observer/filing/0001999480-25-000048.json","markdown":"https://secwatch.observer/filing/0001999480-25-000048.md","text":"https://secwatch.observer/filing/0001999480-25-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1999480/000199948025000048/0001999480-25-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1999480/000199948025000048/alto-20250531.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-20T02:03:00.948682+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}